Q-omics provides the consensus-scored VEZF1P1 profile across patient tissues and cancer cell-line models. VEZF1P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VEZF1P1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, VEZF1P1 RNA expression shows 10,129 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where VEZF1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VEZF1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VEZF1P1 survival associations across molecular data types. VEZF1P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VEZF1P1 RNA expression–survival associations across cancer types. High VEZF1P1 expression shows unfavorable associations in MESO, STAD, LGG and ACC, but favorable associations in KIRC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify MESO as the clearest survival context for VEZF1P1 RNA expression.
This table summarizes VEZF1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VEZF1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VEZF1P1 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in COAD, LIHC and BLCA. The KIRC box plot shows higher VEZF1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .010).
This table shows molecular features associated with VEZF1P1 in patient tissues and cancer cell lines. In patient samples, VEZF1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
